Loading
A phase 2/3 trial testing RO7771950 in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, now recruiting.
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive is a phase 2/3 interventional study registered as NCT07413939, led by Hoffmann-La Roche, and recruiting on the registry. Official title: A Two-part, Seamless, Multicenter, Randomised, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases. Planned enrolment is 650 participants (estimated). The study started in 2026-05-21 and primary completion is expected in 2029-05-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RO7771950, UCSF Helen Diller Family Comprehensive Cancer Center, Roche / Genentech, HER2-positive breast cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer.
Shares Roche / Genentech, HR-positive / HER2-negative breast cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HER2-positive breast cancer.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/